International Journal of Pharmacy and Analytical Research (IJPAR)

IJPAR |Vol.13 | Issue 4 | Oct - Dec -2024

www.ijpar.com

ISSN: 2320-2831

DOI :https://doi.org/10.61096/ijpar.v13.iss4.2024.709-715

Review

A Review on Dissolution Method Development and Validation

Pasupuleti Sunitha*, Shaik Muneer Pasha, Shaistha Tarannum, Siliveru Anil kumar, Souvik Samanta, S .Soumya

Department Of Pharmaceutical Analysis, Teegala Krishna Reddy College Of Pharmacy, Hyderabad, India

*Author for Correspondence: Pasupuleti Sunitha
Email: sunithapasupuletig@gmail.com

Published on: 23 Nov 2024

Published by:
DrSriram Publications

Abstract

Dissolution testing is an essential part of the pharmaceutical quality assurance process, measuring the rate and extent to which the active pharmaceutical ingredient (API) is released from its dosage form in vitro. It is a key determinant of drug bioavailability and, by extension, therapeutic efficacy. With its pivotal role in drug development, dissolution testing requires precise development and validation of methods to ensure consistency, reliability, and compliance with regulatory standards. This review explores the fundamental elements of dissolution method development, including the selection of dissolution medium, apparatus choice, and design parameters that influence dissolution outcomes. Additionally, the review addresses validation protocols necessary to confirm specificity, accuracy, precision, and robustness, as per guidelines from the United States Pharmacopeia (USP), Food and Drug Administration (FDA), and International Council for Harmonisation (ICH). Further, advancements in automation are discussed, demonstrating how modern technologies enhance efficiency, reproducibility, and regulatory compliance. By synthesizing current practices and standards, this review serves as a guide for researchers and professionals engaged in the development and validation of dissolution methods, outlining best practices, key challenges, and future directions.

Keywords: Dissolution method development, validation, pharmaceutical quality control, bioavailability, automation, dissolution medium, apparatus selection.

INTRODUCTION

Dissolution testing is an analytical procedure crucial to pharmaceutical development, serving as a predictor of a drug's bioavailability and, consequently, its clinical efficacy. In the early stages of drug development, dissolution testing helps to assess the performance of solid oral dosage forms like tablets and capsules, which must release their active ingredients effectively to achieve the desired therapeutic effect. Over the decades, dissolution testing has evolved from a simple laboratory procedure to a highly regulated and structured

process, guided by standards set by regulatory authorities such as the FDA and pharmacopeial bodies like the USP[1].

The importance of dissolution testing in pharmaceutical quality control became evident in the 1950s and 60s as scientists began to understand the correlation between dissolution rate and drug absorption in the human body. Today, dissolution testing not only assures the quality of drug products but also supports regulatory approval processes, as dissolution data is often required to demonstrate consistency across batches, bioequivalence, and, for some products, even biowaivers, which allow for certain regulatory approvals without extensive bioavailability testing[2].

The complexity of dissolution testing lies in its reliance on multiple variables, each requiring careful optimization to provide meaningful data. This review discusses the critical factors in dissolution method development, including the choice of dissolution medium and apparatus, as well as the design of study parameters that influence the reproducibility and relevance of the dissolution test. Furthermore, validation of these methods is essential to ensure that the dissolution test is specific, accurate, precise, and robust. Each validation parameter supports the reliability of the dissolution data, allowing it to be used confidently in quality control and regulatory submissions.[3]

Automation has brought significant advancements to dissolution testing, allowing for higher throughput, greater precision, and reduced human error. Fully automated systems can handle the entire dissolution testing process—from medium preparation to sample analysis—facilitating compliance with stringent regulatory requirements and enhancing laboratory efficiency. This review also explores how automated and semi-automated systems have streamlined dissolution testing, making it more efficient and consistent[4].

In sum, this review offers a detailed examination of dissolution method development and validation. It integrates regulatory perspectives, current best practices, and technological advancements, providing a comprehensive guide for scientists and industry professionals working in pharmaceutical quality control.

Dissolution method development

Dissolution method development is the foundation of reliable dissolution testing, requiring a methodical approach to account for the chemical and physical characteristics of the drug substance and its formulation. The goal is to design a procedure that accurately reflects the drug's release profile in a manner that can be reproduced consistently across laboratories and adapted to varying product forms.[5]

Physical and Chemical Properties of the Drug Substance[6]

The properties of the active pharmaceutical ingredient (API) significantly influence the design of a dissolution test. Key factors include solubility, ionization constants, particle size, and polymorphic forms of the API. These factors dictate the selection of the dissolution medium, apparatus, and testing parameters.

1. **Solubility and pH Dependency**: The solubility of the drug in various media is one of the first considerations in method development. APIs that have poor solubility in aqueous media may require the use of surfactants or organic solvents to facilitate dissolution. Moreover, the solubility often varies with pH, making it necessary to test in multiple media with pH ranges that mimic physiological conditions (e.g., pH 1.2 for gastric conditions and pH 6.8 for intestinal conditions).
2. **Ionization Constant (pKa)**: Knowing the pKa of the API is crucial, as it affects the ionization of the drug in different pH environments. This in turn influences its solubility and dissolution rate. For example, weakly acidic drugs may dissolve more readily in basic media, while weakly basic drugs may require acidic media to achieve optimal dissolution.
3. **Particle Size and Surface Area**: The size of drug particles impacts the dissolution rate, with smaller particles generally dissolving more quickly due to increased surface area. Particle size distribution should be controlled during manufacturing, as variability can lead to differences in dissolution behavior.
4. **Crystal Form and Polymorphism**: APIs can exist in different polymorphic forms, each with unique solubility and dissolution properties. Developing a dissolution method requires understanding these variations, as some forms may dissolve more readily than others, affecting the drug's bioavailability.

Selection of Dissolution Medium[5]

The dissolution medium serves as the solvent in which the drug is released, and its composition can impact the test results significantly. When selecting a dissolution medium, developers consider factors such as pH, the presence of surfactants, and the physiological relevance of the medium.

pH Range and Buffers: For oral formulations, the dissolution medium is often selected to replicate the pH conditions of the gastrointestinal tract. The physiological pH ranges from approximately 1.2 in the stomach to 6.8 in the intestines. Buffered solutions help maintain these pH levels throughout the test, which is particularly important for weakly acidic or basic drugs.

Surfactants and Solubility Enhancers: Surfactants such as sodium lauryl sulfate or polysorbate 80 may be added to the medium to improve the solubility of poorly soluble drugs. However, it is essential to balance surfactant

concentration to prevent artificial enhancement of the dissolution rate beyond what is observed in physiological conditions.

Volume and Sink Conditions: A common guideline is to use a volume of medium that is at least three times the amount required to dissolve the maximum dose of the drug, referred to as "sink conditions." Sink conditions ensure that the medium does not become saturated with the drug, which could skew the dissolution rate data.

Selection of Dissolution Apparatus[6]

The choice of dissolution apparatus depends on the dosage form and the characteristics of the API. The USP defines seven types of apparatuses for dissolution testing, each suited to different formulations.

Basket Apparatus (USP Apparatus 1): The basket method is ideal for solid oral dosage forms such as tablets and capsules, particularly those prone to disintegration. The basket rotation speed, usually set between 50-100 rpm, can be adjusted based on the physical characteristics of the dosage form.

Paddle Apparatus (USP Apparatus 2): This apparatus is widely used for immediate-release tablets and capsules. It involves a paddle that stirs the dissolution medium at a specified speed, typically 50-75 rpm. The paddle method is particularly suitable for dosage forms that sink to the bottom of the vessel and require uniform agitation.

Flow-Through Cell (USP Apparatus 4): For modified-release and low-solubility APIs, the flow-through cell provides a controlled environment where dissolution medium is pumped through the cell, maintaining sink conditions. This apparatus is especially useful for sustained-release formulations, implants, and poorly soluble drugs.

Paddle Over Disk and Cylinder Apparatus (USP Apparatuses 5 and 6): These are used for transdermal patches, where the drug must dissolve in media at skin-like conditions.

Each apparatus requires careful calibration and qualification to ensure it provides consistent and accurate data. In some cases, modifications such as using sinkers to prevent floating or adjusting the agitation rate are necessary to improve test reliability.

Study Design and Testing Parameters[7]

The design of a dissolution study includes defining the testing parameters, such as time points, sampling methods, and analysis techniques. For immediate-release products, dissolution is usually measured over a short period, with samples taken at several time points to capture the release profile. Extended-release formulations require longer testing durations, with multiple sampling points to understand the release mechanism.

Time Points and Sampling Intervals: For immediate-release dosage forms, testing intervals are short, often within 30-60 minutes, while extended-release products may require sampling over several hours.

Analytical Techniques: Dissolution samples are commonly analyzed using UV spectrophotometry or high-performance liquid chromatography (HPLC). Spectrophotometry is generally used for single-component formulations, while HPLC is preferable for complex formulations with potential interference from excipients.

Dissolution procedure validation[8]

Validation of dissolution procedures is crucial to ensure that the test provides accurate, consistent, and reliable data across various product batches and manufacturing sites. Validated methods are a requirement for regulatory approval and routine quality control, establishing that a dissolution test can accurately assess the quality and performance of a pharmaceutical product. According to guidelines from the FDA, USP, and ICH, dissolution methods must be validated for a series of parameters, each designed to confirm specific aspects of the method's reliability and applicability.

Validation Parameters

Each parameter addresses a unique aspect of the dissolution process, ensuring the method's suitability across different formulations and production batches.[9]

Specificity

Specificity is the ability of a dissolution method to accurately identify and quantify the API without interference from other components in the formulation, such as excipients, degradants, or other active ingredients. Achieving specificity is essential to ensure that results reflect the dissolution of the target compound alone. For example, in complex formulations, excipients might have overlapping absorbance at the API's analytical wavelength if UV spectrophotometry is used. In such cases, high-performance liquid chromatography (HPLC) is often the preferred technique, providing separation of the API from other formulation components, which helps avoid interference.Specificity can be tested by analyzing the placebo mixture (all excipients without the API) in the dissolution medium. If the placebo exhibits less than 2% interference, the method is considered specific. For products with multiple active ingredients, the method must be validated for each API individually, ensuring that all actives are accurately identified.

Linearity and Range

Linearity refers to the method's ability to produce results that are directly proportional to the concentration of the drug within a specified range. This linear relationship is essential, as it ensures that the dissolution method can accurately quantify the amount of drug released at different stages of the dissolution process.To assess linearity, a series of solutions with increasing concentrations of the API are prepared and measured. Statistical methods, such as linear regression analysis, are used to calculate the correlation coefficient (r), slope, and y-intercept of the regression line. A high correlation coefficient (close to 1.0) indicates a strong linear relationship, verifying the method's suitability within the defined range. For dissolution testing, linearity is typically validated over a range that spans from 20% to 120% of the drug's expected concentration in the medium.[10]

Accuracy and Recovery

Accuracy measures how close the results obtained by the dissolution test are to the true value or reference standard. Accurate methods ensure that the dissolution results reflect the actual amount of API released into the dissolution medium, providing reliable data for quality control and regulatory evaluation.The accuracy of a dissolution method is commonly assessed through recovery studies, where known amounts of the API are added to the dissolution medium and then tested using the dissolution method. The recovery rate should fall within an acceptable range, typically between 95% and 105% of the true value, for the method to be deemed accurate. For complex formulations or those with poor solubility, it may be necessary to dissolve the API in a small amount of organic solvent before adding it to the medium.[11]

Precision[12]

Precision refers to the reproducibility of the dissolution test results, measuring the variability in repeated analyses of a homogeneous sample. Precision is further divided into repeatability, intermediate precision, and reproducibility, each addressing different sources of variability.

Repeatability: Also known as intra-assay precision, repeatability measures the consistency of results within a single laboratory, over a short time period, by the same analyst using the same equipment. For dissolution methods, this often involves repeated measurements on the same batch under identical conditions, with results evaluated for relative standard deviation (RSD).

Intermediate Precision: This parameter, sometimes called inter-day precision, assesses variability within a single laboratory but across different days, analysts, or equipment. It ensures that slight variations in operating conditions or personnel do not significantly impact the dissolution test results.

Reproducibility: Reproducibility measures the method's consistency across different laboratories, often tested through collaborative studies. It is typically required for standardization but may not be necessary if the dissolution method is intended solely for in-house quality control.

For dissolution validation, precision is confirmed if the RSD falls within acceptable limits, which vary depending on regulatory standards and product requirements.

Detection and Quantitation Limits

The detection limit (DL) is the lowest amount of the API that can be detected by the method but not necessarily quantified. It is calculated using signal-to-noise ratios or standard deviation methods. Similarly, the quantitation limit (QL) is the minimum amount that can be reliably quantified with precision and accuracy, typically based on a signal-to-noise ratio of 10:1.DL and QL are particularly important for low-dose products or formulations with minimal release in specific stages. For dissolution testing, QL should be within a range that accommodates the lowest concentration of the drug expected during testing.[13]

Robustness

Robustness refers to the method’s capacity to remain unaffected by small, deliberate variations in procedural parameters, confirming the reliability of the dissolution test under normal usage conditions. Robustness tests often include slight variations in:

- Medium pH and composition
- Agitation speed
- Temperature
- Sampling intervals

If the dissolution results remain consistent despite these variations, the method is considered robust. This ensures that minor procedural changes do not compromise the reliability of the test data.[14]

System Suitability Test

System suitability testing verifies that the dissolution system is functioning correctly before sample testing begins. Parameters for system suitability include theoretical plate count, tailing factor, resolution, and relative standard deviation (RSD) for replicate injections in chromatographic methods. This step is essential to

ensure that the dissolution test conditions are appropriate and that the data generated will be reliable and reproducible.

Validation Guidelines

Regulatory guidelines from the FDA, USP, and ICH emphasize that dissolution methods must be rigorously validated at various stages of drug development and production. During early development, minimal validation data may be sufficient; however, as the drug progresses to late-stage studies or New Drug Application (NDA) submission, full validation data are required. This includes providing evidence of accuracy, precision, specificity, and linearity in accordance with ICH Q2(R1) guidelines. For quality control during production, regular validation or revalidation is conducted to ensure ongoing reliability of the dissolution method.[15]

Automation in dissolution testing

Automation in dissolution testing has introduced considerable efficiencies in the pharmaceutical industry, allowing for higher throughput, reduced variability, and streamlined compliance with regulatory requirements. Automated systems, which vary from semi-automated to fully automated, can handle tasks such as sample preparation, dissolution media replacement, sampling, and data analysis.[16]

Automation

Automation minimizes human intervention, reducing potential sources of error and increasing the reliability of test data. With regulatory standards demanding precise and reproducible dissolution data, automated systems are now integral in many laboratories, supporting both routine quality control and the development of new formulations. The integration of automation into dissolution testing aligns with good laboratory practice (GLP) and good manufacturing practice (GMP) guidelines, facilitating compliance with FDA, EMA, and ICH standards.

Types of Automated Systems[17]

There are two primary types of automated dissolution systems: semi-automated and fully automated systems.

Semi-Automated Systems: In semi-automated systems, certain steps, such as sampling and filtration, are automated, while others, like medium preparation and media change, are performed manually. These systems are cost-effective and suitable for laboratories with moderate throughput requirements, where some manual intervention is feasible.

Fully Automated Systems: Fully automated systems perform the entire dissolution testing process, from medium preparation to sample analysis, without manual intervention. These systems are ideal for high-throughput environments, as they enable rapid testing of multiple samples while maintaining consistent conditions. Additionally, fully automated systems can perform media replacement and manage pH changes during testing, features particularly useful for simulating gastrointestinal transitions in dissolution testing.

Advantages of Automated Dissolution Testing[18]

Automation in dissolution testing offers several advantages:

Enhanced Reproducibility: Automated systems improve reproducibility by maintaining consistent operating conditions, removing variability from manual handling.

Higher Throughput: Laboratories can test multiple samples concurrently, significantly increasing productivity, which is essential for routine quality control and large-scale batch testing.

Compliance and Data Integrity: Automated systems provide electronic data records that facilitate traceability and audit readiness, ensuring compliance with data integrity guidelines outlined by regulatory agencies.

Challenges of Automation

Despite the benefits, automation also presents challenges, including:

Initial Cost and Maintenance: Fully automated systems are expensive to install and require regular maintenance. Laboratories must weigh the upfront investment against long-term gains in productivity and accuracy.

Complex Setup: Automated dissolution systems require rigorous validation and may need customization to match specific formulation requirements, which can complicate setup and increase initial workload.

Future Perspectives in Automation

The integration of artificial intelligence (AI) and machine learning (ML) in automated dissolution systems represents the future of dissolution testing. These technologies can enable real-time data analysis and predictive adjustments to optimize test conditions, improving the efficiency of the dissolution process. For example, AI algorithms can analyze dissolution profiles to predict outliers or adjust test parameters based on historical data, ensuring consistent quality.[19]

Comparative analysis of dissolution testing parameters

This section can present a comparative table of the various parameters involved in dissolution method development and validation, summarizing best practices for each parameter and providing quick references to the preferred approaches for different dosage forms and conditions.[20]

CONCLUSION

Dissolution testing is a fundamental aspect of pharmaceutical quality control, providing insights into the bioavailability and consistency of drug products. Method development and validation are critical steps that ensure the reliability of dissolution data, supporting regulatory compliance and safeguarding patient safety. The growing role of automation, coupled with advancements in AI, promises to further enhance the accuracy and efficiency of dissolution testing, aligning with the industry's commitment to high-quality standards. By adopting best practices in method development, validation, and automation, pharmaceutical companies can achieve robust dissolution testing protocols that meet the demands of modern drug development and regulatory requirements.

REFERENCES

1. McAllister M, Flanagan T, Boon K, Pepin X, Tistaert C, Jamei M, Abend A, Kotzagiorgis E, Mackie C. Developing Clinically Relevant Dissolution Specifications for Oral Drug Products-Industrial and Regulatory Perspectives. Pharmaceutics. 2019 Dec 23;12(1):19. doi: 10.3390/pharmaceutics12010019. PMID: 31878006; PMCID: PMC7022466.
2. Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, Hammett T, Billett L, Behn S, Gibb RC, Abrahamsson B. Clinical relevance of dissolution testing in quality by design. AAPS J. 2008 Jun;10(2):380-90. doi: 10.1208/s12248-008-9034-7. Epub 2008 Aug 7. PMID: 18686045; PMCID: PMC2751384.
3. Nokhodchi A, Chavan S, Ghafourian T. In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances. Pharmaceutics. 2023 Mar 18;15(3):983. doi: 10.3390/pharmaceutics15030983. PMID: 36986844; PMCID: PMC10059005.
4. Abend A, Curran D, Kuiper J, Lu X, Li H, Hermans A, Kotwal P, Diaz DA, Cohen MJ, Zhang L, Stippler E. Dissolution testing in drug product development: workshop summary report. 2019: 1-12. https://link.springer.com/article/10.1208/s12248-018-0288-4
5. Babu BR. Method development and validation for dissolution testings. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2011 Jan;2(1):568. https://www.rjpbcs.com/pdf/2011_2(1)/68.pdf
6. Valkó K. Measurements of physical properties for drug design in industry. InHandbook of analytical separations 2000 Jan 1 (Vol. 1, pp. 535-583). Elsevier Science BV. https://doi.org/10.1016/S1567-7192(00)80015-7
7. Ripal Mistry. A Review : Selection Of Dissolution Media. Cited on Oct 2024. https://www.pharmatutor.org/articles/review-selection-of-dissolution-media
8. Fotaki N, Brown W, Kochling J, Chokshi H, Miao H, Tang K, Gray V. Rationale for selection of dissolution media: three case studies. Dissolut. Technol. 2013 Aug 1;20(3):6-13. https://dissolutiontech.com/DTresour/201308Articles/DT201308_A01.pdf
9. European Medicines Agency, VALIDATION OF ANALYTICAL PRROCEDURE:DEFINITIONS AND METHODOLOGY, ICH Harmonised Tripartite Guideline, June 1995. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-q2r1-validation-analytical-procedures-text-methodology-step-5-first-version_en.pdf
10. Swartz M. Developing and validating dissolution procedures for improved product quality. Pharma Times. 2011;43(2):13-7.https://www.researchgate.net/profile/Michael-Swartz-3/publication/265148414_W_H_I_T_E_Developing_and_Validating_Dissolution_Procedures_for_Improved_Product_Quality/links/556cbbb708aeccd7773be80c/W-H-I-T-E-Developing-and-Validating-Dissolution-Procedures-for-Improved-Product-Quality.pdf
11. Krull, Ira, and Michael Swartz. Developing and validating dissolution procedures. 2008: 188-195.https://www.chromatographyonline.com/view/developing-and-validating-dissolution-procedures-0
12. Marson BM, Concentino V, Junkert AM, Fachi MM, Vilhena RO, Pontarolo R. Validation of analytical methods in a pharmaceutical quality system: An overview focused on HPLC methods. Química Nova. 2020 Oct 16;43:1190-203.https://www.scielo.br/j/qn/a/RwZvtH6LYs5qtbGcVbFMc8c/?lang=en&format=html&stop=next
13. Abdel-Mottaleb MM, Lamprecht A. Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I. Drug development and industrial pharmacy. 2011 Feb 1;37(2):178-84.https://www.tandfonline.com/doi/abs/10.3109/03639045.2010.502534

14. Vaghela B, Kayastha R, Bhatt N, Pathak N, Rathod D. Development and validation of dissolution procedures. Journal of applied pharmaceutical science. 2011 May 30(Issue):50-6. https://japsonline.com/abstract.php?article_id=34
15. Food and Drug Administration. Analytical procedures and methods validation for drugs and biologics. US Department of Health and Human Services. 2015 Jul. https://www.fda.gov/files/drugs/published/Analytical-Procedures-and-Methods-Validation-for-Drugs-and-Biologics.pdf
16. McBride SE, Rogers WA, Fisk AD. Understanding human management of automation errors. Theor Issues Ergon Sci. 2014;15(6):545-577. doi: 10.1080/1463922X.2013.817625. PMID: 25383042; PMCID: PMC4221095.
17. Matthew Knight. Semi-Automated vs Fully Automated: Which one is right for your manufacturing process? 2024. https://www.rnaautomation.com/insight/semi-automated-vs-fully-automated-which-one-is-right-for-your-manufacturing-process/
18. Ibrahim SA, Martini L. Automated dissolution for enteric-coated aspirin tablets: a case study for method transfer to a RoboDis II. Journal of Laboratory Automation. 2014 Aug;19(4):375-80. https://journals.sagepub.com/doi/abs/10.1177/2211068213520401
19. Kapustina O, Burmakina P, Gubina N, Serov N, Vinogradov V. User-friendly and industry-integrated AI for medicinal chemists and pharmaceuticals. Artificial Intelligence Chemistry. 2024 Jul 14:100072. https://www.sciencedirect.com/science/article/pii/S2949747724000307
20. Bredael GM, Liang S, Hahn D. A strategy for quality control dissolution method development for immediate-release solid oral dosage forms. Dissolution Technol. 2015 Jan 1;22:10-6. https://dissolutiontech.com/DTresour/201508Articles/DT201508_A02.pdf